|
|
View Clinical Trial (Medical Research Study)
|
Natural History and Genetic Studies of Usher Syndrome - NCT00106743-20892 (Clinical Trial 124153)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy124153.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Bethesda |
|
State:
|
|
MD |
| Zip Code: |
|
20892 |
| Conditions: |
|
Retinitis Pigmentosa Syndromic - Congenital Deafness - Usher Syndrome - Retinitis Pigmentosa and Deafness - Progressive Hearing Loss - Retinitis Pigmentosa |
| Purpose: |
|
This study will explore clinical and genetic aspects of Usher syndrome, an inherited disease
causing deafness or impaired hearing, visual problems, and, in some cases, unsteadiness or
balance problems. Patients with type 1 Usher syndrome usually are deaf from birth and have
speech and balance problems. Patients with type 2 disease generally are hearing impaired but
have no balance problems. Patients with type 3 disease have progressive hearing loss and
balance problems. All patients develop retinitis pigmentosa, an eye disease that causes poor
night vision and eventually, blindness.
Patients of any age with Usher syndrome may be eligible for this study. Patients who have
had eye and hearing evaluations are asked to send their medical records to the research team
at the National Eye Institute (NEI) for review. They are also asked to have a blood sample
drawn by a medical professional and sent to NEI for genetic analysis. Finally, they are
interviewed about their family histories, particularly about other relative with eye
disease. Patients who have not been evaluated previously have the following tests and
procedures at NIH:
- Family medical history, especially regarding eye disease. A family tree is drawn.
- Blood draw for genetic studies of Usher syndrome.
- Eye examination to assess visual acuity and eye pressure, and to examine pupils, lens,
retina, and eye movements.
- Electroretinogram (ERG) to test the function of visual cells. Wearing eye patches, the
patient sits in a dark room for 30 minutes. Electrodes are taped to the forehead and
the eye patches are removed. The surface of the eye is numbed with eye drops and
contact lenses are placed on the eyes. The patient looks inside a hollow, dark globe
and sees a series of light flashes. Then a light is turned on inside the globe and more
flashes appear. The contact lenses sense small electrical signals generated by the
retina when the light flashes.
- Fluorescein angiography to evaluate the eye's blood vessels. A yellow dye is injected
into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina
are taken using a camera that flashes a blue light into the eye. The pictures show if
any dye has leaked from the vessels into the retina, indicating possible blood vessel
abnormality.
- Hearing tests to help determine the patient's type of Usher syndrome. Tests to evaluate
hearing include examination of both ears with an otoscope, evaluation of the middle ear
and inner ...
|
| Study summary: |
|
Background and Objectives:
The Usher syndromes are a group of clinically variable and genetically heterogeneous
autosomal recessive syndromes. On the basis of clinical findings, at least three types
exist. Patients with Usher type I are born deaf, have vestibular problems, and are thought
to perceive night blindness in early childhood. Patients with Usher type II are born with a
hearing deficit but are able to develop intelligible speech, do not have balance problems;
night vision problems, and visual field changes are noted later. Patients with Usher type
III are born with relatively good hearing that deteriorates over a decade or more; they can
have progressive balance problems and they report night blindness in childhood or teens.
Seven genes have been mapped so far for Usher type I while five of these genes have been
identified. For Usher type II, four genes have been mapped and three of these have been
identified while there is one cloned gene for Usher type III. Quite a lot of information is
still unknown regarding the genetic nature of this syndrome. The picture of the three
clinical types of Usher syndrome has also not been well studied up to this point and cross
sectional studies seems to be the only source of the information available so far, regarding
the natural history of the disease. The aim of this protocol is to better study the natural
history of the disease and also make specific genotype-phenotype correlations.
Study Population:
A total of 200 participants, to include patients affected will all three clinical types of
Usher syndrome and up to 200 unaffected relatives will be enrolled to the protocol.
Unaffected family members, primarily parents and siblings will be enrolled to provide a
blood sample when considered helpful for linkage analysis. Family members will be considered
unaffected if they had a previous normal examination and they don't have any symptoms of
decreased night or peripheral vision.
Methods:
Participants will undergo ophthalmologic, audiologic and vestibular evaluation in order to
be clinically characterized. Blood will be obtained by all participating subjects for the
molecular studies. Patients who cannot come to NIH for participation will be asked to
provide a blood sample for genotyping and a copy of their ophthalmologic, audiology and
vestibular records, to classify phenotype. Each off-site participant will be consented over
the phone by an NEI investigator. All participants will be requested to fill out a
questionnaire.
Outcome Measures:
Affected participants will be phenotypically categorized in one of the three clinical types
based on audiology and vestibular findings. |
| Criteria: |
|
- INCLUSION CRITERIA:
Eligible participants must:
1. have documented neurosensory hearing loss and retinitis pigmentosa and fulfill the
clinical characteristics for USH1, USH2 and USH3 as defined by the Usher syndrome
consortium. ; OR
2. be unaffected family members of a proband with Usher's syndrome, primarily parents
and siblings. Family members will be considered unaffected by history if they have
had previous normal ophthalmologic and hearing examinations and if they don't have
decreased night or peripheral vision.
EXCLUSION CRITERIA:
Patients will be ineligible if they:
1. had an intrauterine infection, perinatal/congenital infections, or intrauterine and
birth complications. These conditions can result in damage to both the auditory or
visual system.
2. have concurrent inherited or acquired conditions that affect the visual and/or
auditory system and significantly alter the phenotype.
Both affected and unaffected individuals will be ineligible if they:
1. Are unwilling or unable to provide a blood sample or unable to undergo the study
procedures.
2. Are younger than 2 years old. |
|
|
|
| Study is available at: |
|
National Eye Institute (NEI), 9000 Rockville Pike
Bethesda, MD 20892
United States
Primary Contact:
Patient Recruitment and Public Liaison Office
Email: prpl@mail.cc.nih.gov
Phone: (800) 411-1222 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 15, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|